
Clinical research for COVID-19 antivirals: Experience from South Africa

Charles Shey Wiysonge
Senior Director
South African Medical Research Council

SAMRC STRATEGIC PLANS PROGRAMMES



GRANTS INNOVATION & PRODUCT DEVELOPMENT PROGRAMMES



SAMRC SHIP PROGRAM

Aim: Support the development of technologies and innovations to address priority diseases and improve delivery of health services - annual budget around R82 million (\$5.5M)

SHIP is loosely based on the Product Development Partnership (PDP) model, but applied in the African context

- 3-year strategy approved by DSI
- Joint decision making on priority areas and awards
- Funds and projects managed by the SAMRC

Focus	HIV	ТВ	NCD	МСН	AMR	Malaria	COVID-19
Treatment	✓	✓	✓	✓		✓	✓
Diagnosis	✓	√	✓	✓	✓		✓
Prevention	✓	✓	✓	✓	✓		✓
Digital Health	✓	√	✓	√	✓	✓	✓
Precision Medicine			✓	√			✓

Investments:

- TB, malaria and NCD drug discovery program at H3D
- HIV vaccine & BNabs program
- HIV trials
- HIV cure research
- TB diagnostics
- TB treatment studies
- NCDs precision medicine
- MCH devices
- AMR surveillance









Home About us ▼

Why register ▼

ap Contact us

Search



+Register User New trial

Welcome to SANCTR







The South African National Clinical Trials Register (SANCTR) provides the public with updated information on clinical trials on human participants being conducted in South Africa. The Register provides you with information on a trials purpose; who can participate, where the trial is located, and contact details.



Additionally, SANCTR is an important tool for monitoring and managing new clinical trials. The questions being investigated, findings of studies as well as mapping of locations, funders, funding, research institutions and progress towards developing new capacity in the area are some of the issues that the register can assist the research community in addressing.

The South African National Clinical Trials Register (SANCTR) provides the public with updated information on clinical trials on human participants being conducted in South Africa. In November 2005 the Department of Health issued a notice that as from the 1st December 2005 all new clinical trials to be conducted in the country must be registered in the South African National Clinical Trials Register. The notice also explained that trials that started recruiting as of 1st July 2005 must also be registered.








Covid-19 treatment trials registered from South Africa by 31 October 2022

- 57 treatment trials, 22 (39%) on antivirals.
- Two phase 1, eleven phase 2, nine were phase 3.

Antivirals	Count	%
Lopinavir-ritonavir	2	9
Nirmatrelvir-Ritonavir	4	18
Nitazoxanide-Ribavirin	1	4.5
Sofosbuvir-Daclatasvir	1	4.5
Molnupiravir Nitazoxanide Bemnifosbuvir	6 4 2	27 18 9
Ensovibep	1	4.5
ATR-002	1	4.5
Triazavirin	1	4.5
Ensitrelvir	1	4.5







NGIYABONGA